Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001992 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00001992: Completed Phase 1 study, sponsored by Genentech.
NCT00001992 is a Phase 1 study that has completed, run by Genentech. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001992, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To test the safety and immunogenicity of rgp 120/HIV-1IIIB vaccine in HIV-1 seropositive adult patients.
Interventions
- BIOLOGICAL rgp120/HIV-1IIIB
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00001992 record still lists
NCT00001992 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which rgp120/HIV-1IIIB is the first listed.
NCT00001992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00001992 about?
NCT00001992 is a clinical study titled "A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers". To test the safety and immunogenicity of rgp 120/HIV-1IIIB vaccine in HIV-1 seropositive adult patients.
What is the current status of trial NCT00001992?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00001992?
The interventions under investigation include: rgp120/HIV-1IIIB (BIOLOGICAL).
Who is sponsoring clinical trial NCT00001992?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.